Citigroup Issues Pessimistic Forecast for Danaher (NYSE:DHR) Stock Price

Danaher (NYSE:DHR) had its target price reduced by stock analysts at Citigroup from $305.00 to $285.00 in a report released on Monday,Benzinga reports. The firm presently has a “buy” rating on the conglomerate’s stock. Citigroup’s price target would indicate a potential upside of 19.71% from the stock’s previous close.

A number of other research firms have also commented on DHR. UBS Group cut their price objective on shares of Danaher from $309.00 to $305.00 and set a “buy” rating for the company in a research report on Wednesday, October 23rd. Evercore ISI lifted their price target on shares of Danaher from $275.00 to $278.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 1st. Royal Bank of Canada lowered their target price on Danaher from $333.00 to $311.00 and set an “outperform” rating for the company in a research note on Wednesday, October 23rd. KeyCorp lifted their target price on shares of Danaher from $290.00 to $310.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 23rd. Finally, StockNews.com lowered Danaher from a “buy” rating to a “hold” rating in a research report on Saturday, December 14th. Six investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $286.80.

Danaher Stock Up 1.4 %

NYSE:DHR traded up $3.23 during trading hours on Monday, hitting $238.07. 3,654,613 shares of the company traded hands, compared to its average volume of 2,664,542. The company has a quick ratio of 1.01, a current ratio of 1.37 and a debt-to-equity ratio of 0.32. The company has a market cap of $171.95 billion, a PE ratio of 45.43, a PEG ratio of 4.33 and a beta of 0.83. The firm’s 50-day simple moving average is $236.37 and its 200-day simple moving average is $254.29. Danaher has a one year low of $222.53 and a one year high of $281.70.

Danaher (NYSE:DHR) last released its quarterly earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share for the quarter, topping the consensus estimate of $1.57 by $0.14. The business had revenue of $5.80 billion for the quarter, compared to analysts’ expectations of $5.59 billion. Danaher had a net margin of 16.39% and a return on equity of 10.62%. The firm’s revenue for the quarter was up 3.1% compared to the same quarter last year. During the same period in the previous year, the company earned $2.02 earnings per share. Equities analysts predict that Danaher will post 7.5 earnings per share for the current year.

Institutional Investors Weigh In On Danaher

Several hedge funds have recently modified their holdings of DHR. Benjamin Edwards Inc. increased its stake in Danaher by 1.8% during the second quarter. Benjamin Edwards Inc. now owns 2,153 shares of the conglomerate’s stock worth $538,000 after acquiring an additional 38 shares during the last quarter. Wedge Capital Management L L P NC grew its stake in shares of Danaher by 3.2% in the third quarter. Wedge Capital Management L L P NC now owns 1,231 shares of the conglomerate’s stock valued at $342,000 after buying an additional 38 shares in the last quarter. Certified Advisory Corp raised its holdings in shares of Danaher by 4.5% during the 2nd quarter. Certified Advisory Corp now owns 926 shares of the conglomerate’s stock valued at $231,000 after buying an additional 40 shares during the period. Meridian Financial Partners LLC boosted its holdings in Danaher by 4.4% in the 3rd quarter. Meridian Financial Partners LLC now owns 957 shares of the conglomerate’s stock worth $266,000 after acquiring an additional 40 shares during the period. Finally, Kovack Advisors Inc. increased its stake in Danaher by 3.4% during the 3rd quarter. Kovack Advisors Inc. now owns 1,243 shares of the conglomerate’s stock worth $346,000 after buying an additional 41 shares during the period. 79.05% of the stock is owned by institutional investors and hedge funds.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.